SG11202008435SA - Pharmaceutical composition including sodium alkyl sulfate - Google Patents
Pharmaceutical composition including sodium alkyl sulfateInfo
- Publication number
- SG11202008435SA SG11202008435SA SG11202008435SA SG11202008435SA SG11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA SG 11202008435S A SG11202008435S A SG 11202008435SA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- composition including
- alkyl sulfate
- sodium alkyl
- including sodium
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052708 sodium Inorganic materials 0.000 title 1
- 239000011734 sodium Substances 0.000 title 1
- -1 sodium alkyl sulfate Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018051620 | 2018-03-19 | ||
| PCT/JP2019/011251 WO2019181876A1 (fr) | 2018-03-19 | 2019-03-18 | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008435SA true SG11202008435SA (en) | 2020-10-29 |
Family
ID=67987327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008435SA SG11202008435SA (en) | 2018-03-19 | 2019-03-18 | Pharmaceutical composition including sodium alkyl sulfate |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11833151B2 (fr) |
| EP (2) | EP3769765B1 (fr) |
| JP (2) | JP6918204B2 (fr) |
| KR (1) | KR102473372B1 (fr) |
| CN (1) | CN111867594A (fr) |
| AU (1) | AU2019239404B2 (fr) |
| BR (1) | BR112020018697A2 (fr) |
| CA (1) | CA3094431C (fr) |
| DK (1) | DK3769765T3 (fr) |
| FI (1) | FI3769765T3 (fr) |
| MA (1) | MA52093A (fr) |
| MX (1) | MX2020009762A (fr) |
| PH (1) | PH12020551412A1 (fr) |
| RU (1) | RU2759746C1 (fr) |
| SG (1) | SG11202008435SA (fr) |
| TW (1) | TWI790364B (fr) |
| WO (1) | WO2019181876A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| MA43807A (fr) | 2016-03-04 | 2018-11-28 | Taiho Pharmaceutical Co Ltd | Préparation et composition de traitement de tumeurs malignes |
| EP3769765B1 (fr) * | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
| KR20210095659A (ko) * | 2018-11-26 | 2021-08-02 | 다이호야쿠힌고교 가부시키가이샤 | 섬유아세포 증식 인자 수용체 저해제와 내분비 요법의 병용에 의한 내분비 요법이 적용되는 종양의 치료 및 예방 방법 |
| TW202404585A (zh) * | 2022-06-10 | 2024-02-01 | 日商大鵬藥品工業股份有限公司 | 含有匹密特匹（Pimitespib）之醫藥組合物 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3433239A1 (de) | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
| FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
| WO1998047499A1 (fr) * | 1997-04-22 | 1998-10-29 | Nippon Kayaku Kabushiki Kaisha | Preparations a base de flutamide et leurs procedes de preparation |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| DK1301472T3 (da) | 2000-07-19 | 2014-04-07 | Warner Lambert Co | Oxygenerede estere af 4-iod-phenylamino-benzhydroxamsyrer |
| KR100984613B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| EP1689387B1 (fr) | 2003-11-19 | 2011-09-14 | Array Biopharma, Inc. | Inhibiteurs bicycliques de mek et leurs procedes de production |
| DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| PL1761528T3 (pl) | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
| CN101065358B (zh) | 2004-10-20 | 2015-03-11 | 默克雪兰诺有限公司 | 3-芳基氨基吡啶衍生物 |
| US20080207665A1 (en) * | 2005-06-17 | 2008-08-28 | Pfizer Inc. | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists |
| PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
| US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
| EP1971601B1 (fr) | 2005-11-15 | 2009-10-21 | Array Biopharma Inc. | Derivés de la n4-phényl-quinazoline-4-amine et composés similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives |
| TW200738725A (en) | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
| MX2008013675A (es) | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal. |
| EP1939197A1 (fr) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | Derivés de 8-éthinylxanthine comme antagonistes selectives du recepteur A2A |
| WO2008093855A1 (fr) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Composition destinée au traitement d'un cancer de l'estomac de type indifférencié |
| EP2561875A3 (fr) | 2007-03-28 | 2013-06-12 | Pharmacyclics, Inc. | Inhibiteurs de la tyrosine kinase de bruton |
| ME00936B (fr) | 2007-04-10 | 2012-06-20 | Exelixis Inc | Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone |
| EP2203181B1 (fr) * | 2007-10-16 | 2018-02-14 | Biocon Limited | Composition pharmaceutique solide administrable par voie orale et procédé associé |
| BRPI0914233A2 (pt) | 2008-06-19 | 2015-11-03 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito inibidor de fgfr e para produzir um efeito anticâncer em um animal de sangue quente, composição farmacêutica, e, método para tratar uma doença |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| EP2424843B1 (fr) | 2009-04-30 | 2014-03-26 | Novartis AG | Dérivés d'imidazole et leur utilisation comme modulateurs des kinases dépendantes des cyclines |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| US9140689B2 (en) | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| DE102011015188A1 (de) | 2010-03-29 | 2011-09-29 | Herbert Kannegiesser Gmbh | Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen |
| EP2554169B1 (fr) * | 2010-03-29 | 2019-11-20 | EA Pharma Co., Ltd. | Préparation pharmaceutique comprenant un dérivé de phénylalanine |
| CN103153311A (zh) | 2010-06-03 | 2013-06-12 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| MX342064B (es) | 2011-04-06 | 2016-09-12 | Taiho Pharmaceutical Co Ltd | Novedoso compuesto de imidazo-oxazina o sal del mismo. |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| DK2657233T3 (da) | 2012-01-19 | 2014-09-22 | Taiho Pharmaceutical Co Ltd | 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf |
| IN2014DN05869A (fr) | 2012-01-31 | 2015-05-22 | Novartis Ag | |
| ES2581065T3 (es) | 2012-02-23 | 2016-08-31 | Bayer Intellectual Property Gmbh | Benzotienil-pirrolotriazinas sustituidas y usos de las mismas |
| KR20160128456A (ko) | 2012-07-02 | 2016-11-07 | 다이호야쿠힌고교 가부시키가이샤 | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| EP2922955B1 (fr) | 2012-11-26 | 2019-03-06 | Roche Innovation Center Copenhagen A/S | Compositions et méthodes pour la modulation de l'expression de fgfr3 |
| RU2015137610A (ru) | 2013-03-06 | 2017-04-10 | Дженентек, Инк. | Способы лечения и профилактики лекарственной резистентности злокачественных опухолей |
| SI2986610T1 (en) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Bicyclic heterocycles as inhibitors of FGFR |
| TWI626443B (zh) | 2013-06-20 | 2018-06-11 | Taiho Pharmaceutical Co Ltd | 基於ＰＨＬＤＡ１或ＰＩＫ３Ｃ２Ｂ表現之ＰＩＫ３／ＡＫＴ／ｍＴＯＲ抑制劑之治療效果的預測方法 |
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| WO2015008844A1 (fr) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Agent thérapeutique pour un cancer résistant à un inhibiteur de fgfr |
| US10703798B2 (en) * | 2014-03-31 | 2020-07-07 | Debiopharm International Sa | Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL) |
| KR102412321B1 (ko) | 2014-04-25 | 2022-06-22 | 추가이 세이야쿠 가부시키가이샤 | 4환성 화합물을 고용량 함유하는 제제 |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2015173853A1 (fr) * | 2014-05-12 | 2015-11-19 | 株式会社日立製作所 | Dispositif de traitement d'informations, procédé de traitement de celui-ci, et dispositif d'entrée/sortie |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41350A (fr) | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| EP3750530A1 (fr) | 2015-02-05 | 2020-12-16 | TyrNovo Ltd. | Combinaisons de doubles modulateurs d'irs/stat3 et d'agents anticancéreux pour le traitement du cancer |
| WO2016130917A1 (fr) | 2015-02-12 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Traitement contre le cancer à action synergique |
| JPWO2016136928A1 (ja) | 2015-02-27 | 2017-08-31 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| DK3279202T3 (da) | 2015-03-31 | 2020-08-17 | Taiho Pharmaceutical Co Ltd | Krystal af 3,5-disubstitueret benzenalkynylforbindelse |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US10532056B2 (en) | 2015-06-29 | 2020-01-14 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| EP3120851A1 (fr) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6- (2,6-dichlorophényl) -8-methyl-2-(phénylamino) -pyrido[2,3-d]pyrimidin-7-(8h)-one pour le traitement de cancers solides |
| AU2016300175A1 (en) * | 2015-07-24 | 2018-03-01 | Debiopharm International Sa | FGFR expression and susceptibility to an FGFR inhibitor |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| WO2017086332A1 (fr) | 2015-11-19 | 2017-05-26 | 国立大学法人金沢大学 | Agent thérapeutique pour le traitement de cancers de type à mutation de kras mésenchymateux |
| MA43807A (fr) * | 2016-03-04 | 2018-11-28 | Taiho Pharmaceutical Co Ltd | Préparation et composition de traitement de tumeurs malignes |
| JP2018002662A (ja) | 2016-07-01 | 2018-01-11 | 大鵬薬品工業株式会社 | キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体 |
| JP6296308B1 (ja) | 2016-09-26 | 2018-03-20 | ツジカワ株式会社 | ロール装置 |
| WO2018130928A1 (fr) | 2017-01-10 | 2018-07-19 | Novartis Ag | Combinaison pharmaceutique comprenant un inhibiteur d'alk et un inhibiteur de shp2 |
| EP3769765B1 (fr) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
| AU2018448845B2 (en) | 2018-11-09 | 2022-03-24 | Taiho Pharmaceutical Co., Ltd. | Method for producing dimethoxybenzene compound |
| CN113260618A (zh) | 2018-11-09 | 2021-08-13 | 大鹏药品工业株式会社 | 二甲氧基苯化合物类似物、分析所述化合物的方法和所述化合物的标准品 |
| KR20210095659A (ko) | 2018-11-26 | 2021-08-02 | 다이호야쿠힌고교 가부시키가이샤 | 섬유아세포 증식 인자 수용체 저해제와 내분비 요법의 병용에 의한 내분비 요법이 적용되는 종양의 치료 및 예방 방법 |
| WO2020170355A1 (fr) | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Procede pour le traitement de tumeurs a variant du fgfr1 |
| MA55091A (fr) | 2019-02-28 | 2022-01-05 | Taiho Pharmaceutical Co Ltd | Thérapie anticancéreuse faisant appel à un composé benzène-alcynyle 3,5-disubstitué et au pembrolizumab |
| JPWO2020256096A1 (fr) | 2019-06-21 | 2020-12-24 |
-
2019
- 2019-03-18 EP EP19771998.2A patent/EP3769765B1/fr active Active
- 2019-03-18 US US16/982,377 patent/US11833151B2/en active Active
- 2019-03-18 JP JP2020507802A patent/JP6918204B2/ja active Active
- 2019-03-18 MA MA052093A patent/MA52093A/fr unknown
- 2019-03-18 KR KR1020207029418A patent/KR102473372B1/ko active IP Right Grant
- 2019-03-18 WO PCT/JP2019/011251 patent/WO2019181876A1/fr unknown
- 2019-03-18 AU AU2019239404A patent/AU2019239404B2/en active Active
- 2019-03-18 CN CN201980020022.5A patent/CN111867594A/zh active Pending
- 2019-03-18 TW TW108109195A patent/TWI790364B/zh active
- 2019-03-18 DK DK19771998.2T patent/DK3769765T3/da active
- 2019-03-18 FI FIEP19771998.2T patent/FI3769765T3/fi active
- 2019-03-18 EP EP24160537.7A patent/EP4353222A1/fr active Pending
- 2019-03-18 MX MX2020009762A patent/MX2020009762A/es unknown
- 2019-03-18 RU RU2020133810A patent/RU2759746C1/ru active
- 2019-03-18 BR BR112020018697-0A patent/BR112020018697A2/pt unknown
- 2019-03-18 CA CA3094431A patent/CA3094431C/fr active Active
- 2019-03-18 SG SG11202008435SA patent/SG11202008435SA/en unknown
-
2020
- 2020-09-09 PH PH12020551412A patent/PH12020551412A1/en unknown
-
2021
- 2021-07-19 JP JP2021118771A patent/JP7322103B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3769765T3 (da) | 2024-05-13 |
| FI3769765T3 (fi) | 2024-05-15 |
| JP6918204B2 (ja) | 2021-08-11 |
| CA3094431A1 (fr) | 2019-09-26 |
| KR102473372B1 (ko) | 2022-12-05 |
| TWI790364B (zh) | 2023-01-21 |
| RU2759746C1 (ru) | 2021-11-17 |
| US20210030755A1 (en) | 2021-02-04 |
| EP3769765A4 (fr) | 2021-12-15 |
| AU2019239404B2 (en) | 2021-12-23 |
| BR112020018697A2 (pt) | 2020-12-29 |
| PH12020551412A1 (en) | 2021-09-01 |
| MX2020009762A (es) | 2021-01-08 |
| EP3769765B1 (fr) | 2024-04-17 |
| TW201938564A (zh) | 2019-10-01 |
| CN111867594A (zh) | 2020-10-30 |
| JPWO2019181876A1 (ja) | 2020-10-08 |
| JP7322103B2 (ja) | 2023-08-07 |
| EP3769765A1 (fr) | 2021-01-27 |
| MA52093A (fr) | 2021-01-27 |
| US11833151B2 (en) | 2023-12-05 |
| WO2019181876A1 (fr) | 2019-09-26 |
| JP2021167346A (ja) | 2021-10-21 |
| EP4353222A1 (fr) | 2024-04-17 |
| AU2019239404A1 (en) | 2020-11-05 |
| CA3094431C (fr) | 2023-06-27 |
| KR20200131873A (ko) | 2020-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3769765T3 (fi) | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus | |
| IL280135A (en) | Sodium Alagolix Compositions and Processes | |
| EP4125815A4 (fr) | Compositions thérapeutiques | |
| GB201804548D0 (en) | Pharmaceutical compositions | |
| GB201818164D0 (en) | New composition | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| PT3834893T (pt) | Composição ignífuga | |
| SI3749673T1 (sl) | Kristalinična oblika biktegravir natrija | |
| GB201807053D0 (en) | Pharmaceutical composition | |
| SG11202103374TA (en) | Pharmaceutical composition | |
| PT3632436T (pt) | Composição farmacêutica compreendendo sais de lenvatinib | |
| GB201808571D0 (en) | Pharmaceutical compositions | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| FI3908321T3 (fi) | Farmaseuttinen koostumus | |
| EP4081251A4 (fr) | Compositions pharmaceutiques | |
| GB201919180D0 (en) | New composition of matter | |
| GB201808567D0 (en) | Pharmaceutical compositions | |
| PT3414211T (pt) | Composição de reboco | |
| ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
| GB201820689D0 (en) | Pharmaceutical composition | |
| IL292715A (en) | Soap preparation | |
| GB201810265D0 (en) | New pharmaceutical compositions | |
| GB201810261D0 (en) | New pharmaceutical compositions | |
| PT3749673T (pt) | Forma cristalina de bictegravir sódico | |
| IL285728A (en) | Pharmaceutical composition |